{"id":3003,"date":"2017-07-13T06:30:00","date_gmt":"2017-07-13T06:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/primecc-studien-fardigrekryterad\/"},"modified":"2017-07-13T06:30:00","modified_gmt":"2017-07-13T06:30:00","slug":"primecc-studien-fardigrekryterad","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/primecc-studien-fardigrekryterad\/","title":{"rendered":"PrimECC studien f\u00e4rdigrekryterad"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong>PrimECC<sup>\u00ae<\/sup> \u00e4r en CE-m\u00e4rkt och patentskyddad produkt, som \u00e4r utvecklad f\u00f6r att f\u00f6rbereda (priming p\u00e5 engelska) hj\u00e4rtlungmaskiner inf\u00f6r \u00f6ppen hj\u00e4rtkirurgi. En tidigare \u2019proof of concept\u2019 studie som gjorts med PrimECC<sup>\u00ae<\/sup> p\u00e5visar intressanta kliniska resultat. Den studie som nu f\u00e4rdigrekryterats har f\u00f6r avsikt att ut\u00f6ka den kliniska dokumentationen f\u00f6r PrimECC<sup>\u00ae<\/sup> och inkluderade totalt 80 patienter. Analys av resultaten kommer nu att p\u00e5b\u00f6rjas och den f\u00f6rsta publikationen fr\u00e5n studien \u00e4r ber\u00e4knad till senare delen av 2017.<\/strong><\/div>\n<p><span>Det sker flera hundratusen hj\u00e4rtoperationer per \u00e5r i v\u00e4rlden d\u00e5 hj\u00e4rtlungmaskin anv\u00e4nds och den tidigare \u2019proof of concept\u2019 studie som gjorts med PrimECC<sup>\u00ae<\/sup> indikerar att patienten f\u00e5r f\u00f6rb\u00e4ttrad v\u00e4tskebalans efter operationen om hj\u00e4rtlungmaskinen preparerats med PrimECC<sup>\u00ae<\/sup>, ist\u00e4llet f\u00f6r med de enklare l\u00f6sningar som ofta anv\u00e4nds. Under det senaste \u00e5ret har f\u00f6retaget genomf\u00f6rt en randomiserad blindad klinisk studie p\u00e5 80 patienter vid Sahlgrenska Universitetssjukhuset i G\u00f6teborg f\u00f6r att ut\u00f6ka dokumentationen. Alla patienter \u00e4r nu inkluderade och de f\u00f6rsta resultaten ber\u00e4knas publiceras under senare delen av 2017.<\/span><\/p>\n<p><span>Studieansvarig Professor Anders Jeppsson \u00e4r n\u00f6jd med att rekryteringen av patienter g\u00e5tt planenligt och ser med intresse framemot att analysera resultaten.<\/span><\/p>\n<p><span>XVIVO Perfusion avvaktar analys av resultaten fr\u00e5n studien vid Sahlgrenska Universitetssjukhuset och planerar inte n\u00e5gon omfattande lansering av produkten innan resultat fr\u00e5n studien \u00e4r publicerade. XVIVO Perfusion har beviljats patent p\u00e5 PrimECC<sup>\u00ae<\/sup> i USA, EU, Kina och Japan.<\/span><\/p>\n<p><span>PrimECC<\/span><strong><span><sup>\u00ae<\/sup><\/span><\/strong><span> \u00e4r en v\u00e4tska som utvecklats i samarbete med Professor Stig Steen i Lund, f\u00f6r att f\u00f6rbereda hj\u00e4rtlungmaskiner f\u00f6re anv\u00e4ndning. Dessa maskiner anv\u00e4nds f\u00f6r att driva blodcirkulationen och ta \u00f6ver syres\u00e4ttningen av blodet ist\u00e4llet f\u00f6r hj\u00e4rta och lungor under hj\u00e4rtoperationer. V\u00e4tskan \u00e4r till f\u00f6r att kompensera f\u00f6r den blodvolym som under operationen finns utanf\u00f6r patienten, i hj\u00e4rtlungmaskinen. Idag anv\u00e4nds som regel enkla saltl\u00f6sningar som inte \u00e4r optimerade f\u00f6r detta \u00e4ndam\u00e5l. Syftet med PrimECC<sup>\u00ae<\/sup> \u00e4r att minska biverkningar som kan uppst\u00e5 vid och efter anv\u00e4ndning av hj\u00e4rtlungmaskin. <\/span><\/p>\n<p><span>\u201dDet \u00e4r mycket gl\u00e4djande att den kliniska studien med PrimECC<sup>\u00ae<\/sup> nu \u00e4r f\u00e4rdigrekryterad d\u00e5 produkten har en intressant klinisk och kommersiell potential. Vi ser fram emot resultaten fr\u00e5n studien som ber\u00e4knas komma senare i \u00e5r\u201d s\u00e4ger XVIVO Perfusions VD Magnus Nilsson. <\/span><\/p>\n<p><span>G\u00f6teborg 13 juli 2017<br \/><\/span>Magnus Nilsson, VD<br \/>XVIVO Perfusion AB (publ)<\/p>\n<div class=\"mfn-footer\">\n<p><span>F\u00f6r ytterligare information, v\u00e4nligen kontakta: <\/span><\/p>\n<p><span>Christoffer Rosenblad, CFO, +1\u00a0720\u00a0616 2101, christoffer.rosenblad@xvivoperfusion.com<br \/>Magnus Nilsson, VD, +46 31-788 21 50, magnus.nilsson@xvivoperfusion.com<\/span><\/p>\n<p><span>F\u00f6r ytterligare information om XVIVO Perfusions verksamhet h\u00e4nvisas till bolagets hemsida, www.xvivoperfusion.com<\/span><\/p>\n<p><span>Denna information \u00e4r s\u00e5dan information som Xvivo Perfusion AB (publ) \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersons f\u00f6rsorg, f\u00f6r offentligg\u00f6rande klockan 8:30 den 13 juli 2017.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>PrimECC\u00ae \u00e4r en CE-m\u00e4rkt och patentskyddad produkt, som \u00e4r utvecklad f\u00f6r att f\u00f6rbereda (priming p\u00e5 engelska) hj\u00e4rtlungmaskiner inf\u00f6r \u00f6ppen hj\u00e4rtkirurgi&#8230;.<\/p>\n","protected":false},"template":"","class_list":["post-3003","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-mar","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-other"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PrimECC studien f\u00e4rdigrekryterad - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/primecc-studien-fardigrekryterad\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PrimECC studien f\u00e4rdigrekryterad - XVIVO\" \/>\n<meta property=\"og:description\" content=\"PrimECC\u00ae \u00e4r en CE-m\u00e4rkt och patentskyddad produkt, som \u00e4r utvecklad f\u00f6r att f\u00f6rbereda (priming p\u00e5 engelska) hj\u00e4rtlungmaskiner inf\u00f6r \u00f6ppen hj\u00e4rtkirurgi....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/primecc-studien-fardigrekryterad\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/primecc-studien-fardigrekryterad\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/primecc-studien-fardigrekryterad\\\/\",\"name\":\"PrimECC studien f\u00e4rdigrekryterad - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2017-07-13T06:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/primecc-studien-fardigrekryterad\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/primecc-studien-fardigrekryterad\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/primecc-studien-fardigrekryterad\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PrimECC studien f\u00e4rdigrekryterad\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PrimECC studien f\u00e4rdigrekryterad - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/primecc-studien-fardigrekryterad\/","og_locale":"en_US","og_type":"article","og_title":"PrimECC studien f\u00e4rdigrekryterad - XVIVO","og_description":"PrimECC\u00ae \u00e4r en CE-m\u00e4rkt och patentskyddad produkt, som \u00e4r utvecklad f\u00f6r att f\u00f6rbereda (priming p\u00e5 engelska) hj\u00e4rtlungmaskiner inf\u00f6r \u00f6ppen hj\u00e4rtkirurgi....","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/primecc-studien-fardigrekryterad\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/primecc-studien-fardigrekryterad\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/primecc-studien-fardigrekryterad\/","name":"PrimECC studien f\u00e4rdigrekryterad - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2017-07-13T06:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/primecc-studien-fardigrekryterad\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/primecc-studien-fardigrekryterad\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/primecc-studien-fardigrekryterad\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"PrimECC studien f\u00e4rdigrekryterad"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3003","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3003"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}